Enovis Corporation (ENOV)
NYSE: ENOV · IEX Real-Time Price · USD
+0.21 (0.42%)
May 24, 2024, 4:00 PM EDT - Market closed

Company Description

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide.

It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy.

The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals.

The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools.

The company distributes its products through independent distributors and directly under the ESAB and DJO brands.

Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

Enovis Corporation
Enovis logo
Country United States
Founded 1995
IPO Date May 8, 2008
Industry Specialty Industrial Machinery
Sector Industrials
Employees 6,550
CEO Matthew L. Trerotola

Contact Details

2711 Centerville Road, Suite 400
Wilmington, Delaware 19808
United States
Phone (302) 252-9160
Website enovis.com

Stock Details

Ticker Symbol ENOV
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001420800
CUSIP Number 194014502
ISIN Number US1940145022
Employer ID 54-1887631
SIC Code 3842

Key Executives

Name Position
Matthew L. Trerotola Chief Executive Officer and Chairman
Phillip Benjamin Berry Senior Vice President and Chief Financial Officer
Patricia A. Lang Senior Vice President and Chief Human Resources Officer
Daniel A. Pryor Executive Vice President of Strategy and Business Development
Brady R. Shirley Executive Advisor and Director
John Kleckner Vice President, Controller and Chief Accounting Officer
Derek Leckow Vice President of Investor Relations
Bradley J. Tandy Senior Vice President and Chief Legal Officer
Katie Sweet Vice President of Corporate Communication
Terry Ross Group President Prevention and Recovery

Latest SEC Filings

Date Type Title
May 22, 2024 8-K Current Report
May 2, 2024 10-Q Quarterly Report
May 2, 2024 8-K Current Report
Apr 5, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 5, 2024 DEF 14A Other definitive proxy statements
Apr 5, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Mar 25, 2024 PRE 14A Other preliminary proxy statements
Feb 22, 2024 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
Feb 22, 2024 10-K Annual Report
Feb 22, 2024 8-K Current Report